Affinity of Tau antibodies for solubilized pathological Tau species but not their immunogen or insoluble Tau aggregates predicts in vivo and ex vivo efficacy-Reference-Cited by-同舟云学术

Affinity of Tau antibodies for solubilized pathological Tau species but not their immunogen or insoluble Tau aggregates predicts in vivo and ex vivo efficacy

Published:2016-08-30 Issue:1 Volume:11 Page:
ISSN:1750-1326
Container-title:Molecular Neurodegeneration
language:en
Short-container-title:Mol Neurodegeneration

Author:

Congdon Erin E.,Lin Yan,Rajamohamedsait Hameetha B.,Shamir Dov B.,Krishnaswamy Senthilkumar,Rajamohamedsait Wajitha J.,Rasool Suhail,Gonzalez Veronica,Levenga Josien,Gu Jiaping,Hoeffer Charles,Sigurdsson Einar M.

Funder

National Institutes of Health

Blas Frangione Foundation

Alzheimer's Association

Publisher

Springer Science and Business Media LLC

Subject

Cellular and Molecular Neuroscience,Neurology (clinical),Molecular Biology

Link

http://link.springer.com/content/pdf/10.1186/s13024-016-0126-z.pdf

Reference46 articles.

1. Asuni AA, et al. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci. 2007;27(34):9115–29.